For biopharmaceutical companies, Japan is one of the world’s most important markets, but also among the most operationally complex. Many therapies with strong global clinical validation still face significant barriers to successful market entry, not due to scientific limitations, but because regulatory strategy, operational readiness, supply planning, and commercialization are not aligned early in the process. Although regulatory planning, business operations preparation, and supply planning are closely interconnected, they are often managed separately. This fragmented approach increases execution risk, delays timelines, and reduces the feasibility of market entry. PATH Solution was developed to address this gap by integrating these critical elements from the outset. It provides an end to end, execution focused framework spanning market feasibility and regulatory strategy through approval, launch, stable supply, and post launch operations. By aligning strategic planning with operationa